Search company, investor...

Predict your next investment

Teva Pharmaceuticals company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
tevapharm.com

Investments

15

Portfolio Exits

12

Partners & Customers

10

About Teva Pharmaceuticals

Teva Pharmaceutical Industries, headquartered in Israel, is a generic pharmaceutical company. Teva develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients.

Headquarters Location

5 Basel St.

Petah Tikva, 49131,

Israel

+972-3-9267267

Want to inform investors similar to Teva Pharmaceuticals about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Teva Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Teva Pharmaceuticals in 3 Expert Collections, including Conference Exhibitors.

C

Conference Exhibitors

5,302 items

M

Medical Devices

295 items

Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA

B

Biopharma Tech

260 items

Research containing Teva Pharmaceuticals

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Teva Pharmaceuticals in 2 CB Insights research briefs, most recently on Apr 19, 2021.

Latest Teva Pharmaceuticals News

Worldwide Substance Abuse Treatment Industry to 2030 - Rise in the Number of Opioid Prescriptions Drives Growth - ResearchAndMarkets.com

Jan 27, 2023

Teva Pharmaceuticals Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global substance abuse treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global substance abuse treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global substance abuse treatment market. In-depth competitive environment analysis and historical years (2020) market size data are also provided in the report. Thus, the research study provides a holistic view of the global substance abuse treatment market, offering market size and estimates for the period from 2020 to 2030, keeping in mind the above-mentioned factors. Substance abuse is a compulsive, excessive, and self-damaging use of habit forming drugs or substances; leading to addiction, dependence, serious physiological injury, psychological harm or death. Factors such as alarming rise in the number of substance addicted population, rise in the number of opioid prescriptions written by physicians, increased government intervention and encouragement to curb substance abuse in all countries are driving the growth of substance abuse treatment market globally. However, low treatment compliance may negatively impact the growth of market. In the base year 2016, drug abuse treatment held largest market share due to the factors such as higher alarming rise in the number of drug addicted population, increased government intervention and encouragement to curb substance abuse and rise in the number of opioid prescriptions written by physicians are driving the growth of drug abuse treatment market globally. In the base year 2020, North America dominated the substance abuse treatment market in terms of revenue and it is anticipated that it will show significant growth during the forecast period; U.S. was observed as largest regional market in North America. Factors such as alarming rise in the number of addicted population, government initiatives in substance abuse prevention and treatment, high awareness about the threats to life and economic burden, and evolved government policies for the same are the prime contributors to the dominance of North America. Expenditure on healthcare is highest in the U.S. as compared to other nations. It is anticipated that Asia Pacific will grow at highest CAGR during the forecast period due to developing economic condition, improvement in awareness among general patient population, improved treatment access, growing addiction rates along with rise in awareness and evolution of healthcare infrastructure would fuel the growth during the forecast period. Historical & Forecast Period This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030. Key questions answered in this report What are the key micro and macro environmental factors that are impacting the growth of Substance Abuse Treatment market? What are the key investment pockets with respect to product segments and geographies currently and during the forecast period? Estimated forecast and market projections up to 2030. Which segment accounts for the fastest CAGR during the forecast period? Which market segment holds a larger market share and why? Are low and middle-income economies investing in the Substance Abuse Treatment market? Which is the largest regional market for Substance Abuse Treatment market? What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa? Which are the key trends driving Substance Abuse Treatment market growth? Who are the key competitors and what are their key strategies to enhance their market presence in the Substance Abuse Treatment market worldwide? For more information about this report visit https://www.researchandmarkets.com/r/tdw1wq-abuse?w=4 Contacts

Teva Pharmaceuticals Investments

15 Investments

Teva Pharmaceuticals has made 15 investments. Their latest investment was in Remedix as part of their Corporate Minority - II on September 9, 2019.

CBI Logo

Teva Pharmaceuticals Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/9/2019

Corporate Minority - II

Remedix

Yes

1

5/18/2017

Corporate Minority

Heptares Therapeutics

$5M

Yes

2

6/18/2015

Corporate Minority - II

Keratin Biosciences

$35M

Yes

1

6/2/2015

Corporate Minority

Subscribe to see more

Subscribe to see more

10

5/15/2012

Series E

Subscribe to see more

$99M

Subscribe to see more

0

Date

9/9/2019

5/18/2017

6/18/2015

6/2/2015

5/15/2012

Round

Corporate Minority - II

Corporate Minority

Corporate Minority - II

Corporate Minority

Series E

Company

Remedix

Heptares Therapeutics

Keratin Biosciences

Subscribe to see more

Subscribe to see more

Amount

$5M

$35M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

2

1

10

0

Teva Pharmaceuticals Portfolio Exits

12 Portfolio Exits

Teva Pharmaceuticals has 12 portfolio exits. Their latest portfolio exit was Immuneering on July 30, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/30/2021

IPO

$99M

Public

6

9/17/2020

IPO

$99M

Public

11

10/26/2018

IPO

$99M

Public

4

8/9/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

2/2/2018

Acq - Fin

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/30/2021

9/17/2020

10/26/2018

8/9/2018

2/2/2018

Exit

IPO

IPO

IPO

IPO

Acq - Fin

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Public

Subscribe to see more

Subscribe to see more

Sources

6

11

4

10

10

Teva Pharmaceuticals Acquisitions

15 Acquisitions

Teva Pharmaceuticals acquired 15 companies. Their latest acquisition was Allergan - Anda Distribution Business on August 05, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/5/2016

$99M

Acquired Unit

1

8/2/2016

$99M

Acquired Unit

4

7/27/2016

$99M

Acquired Unit

4

10/1/2015

Subscribe to see more

$99M

Subscribe to see more

10

9/25/2015

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/5/2016

8/2/2016

7/27/2016

10/1/2015

9/25/2015

Investment Stage

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

Note

Acquired Unit

Acquired Unit

Acquired Unit

Subscribe to see more

Subscribe to see more

Sources

1

4

4

10

10

Teva Pharmaceuticals Partners & Customers

10 Partners and customers

Teva Pharmaceuticals has 10 strategic partners and customers. Teva Pharmaceuticals recently partnered with HealthSnap on November 11, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

11/14/2022

Partner

United States

Teva Announces Unique Collaboration with HealthSnap to Expand the Reach of its Respiratory Digital Health Platform

HealthSnap is continuously seeking partnerships and we look forward to delivering quality at home programs with this new and exciting collaboration with Teva Pharmaceuticals , '' said Samson Magid , Co-Founder and CEO of HealthSnap .

3

11/14/2022

Partner

United States

Teva, Rimidi team up to integrate respiratory digital health data

Teva said its U.S. affiliate is collaborating with clinical management platform Rimidi to expand the reach of its respiratory digital health platform .

5

10/25/2022

Partner

United States

Clinics Across Florida, New Jersey & California Advancing Mental Health in Underserved Communities – Awarded Funding from Teva Pharmaceuticals, Direct Relief and NAFC.

Community Routes : Access to Mental Healthcare , a partnership between Direct Relief , the National Association of Free and Charitable Clinics , and Teva Pharmaceuticals , provides awards to support clinics expanding access to mental health services across three states .

2

10/18/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

10/18/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

11/14/2022

11/14/2022

10/25/2022

10/18/2022

10/18/2022

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

United States

United States

United States

United States

United States

News Snippet

Teva Announces Unique Collaboration with HealthSnap to Expand the Reach of its Respiratory Digital Health Platform

HealthSnap is continuously seeking partnerships and we look forward to delivering quality at home programs with this new and exciting collaboration with Teva Pharmaceuticals , '' said Samson Magid , Co-Founder and CEO of HealthSnap .

Teva, Rimidi team up to integrate respiratory digital health data

Teva said its U.S. affiliate is collaborating with clinical management platform Rimidi to expand the reach of its respiratory digital health platform .

Clinics Across Florida, New Jersey & California Advancing Mental Health in Underserved Communities – Awarded Funding from Teva Pharmaceuticals, Direct Relief and NAFC.

Community Routes : Access to Mental Healthcare , a partnership between Direct Relief , the National Association of Free and Charitable Clinics , and Teva Pharmaceuticals , provides awards to support clinics expanding access to mental health services across three states .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

5

2

10

10

Teva Pharmaceuticals Team

69 Team Members

Teva Pharmaceuticals has 69 team members, including current President, Mike Netz.

Name

Work History

Title

Status

Mike Netz

President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Mike Netz

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Teva Pharmaceuticals to Competitors

B
BRAVIS

BRAVIS is a software and system house. It develops high-end internet-based video conference systems.

Pfizer Logo
Pfizer

Pfizer (NYSE: PFE) offers a diversified health care portfolio including human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer products. It works across various markets to promote wellness, prevention, treatments, and cures that challenge feared diseases. The company collaborates with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. The company was founded in 1849 and is based in New York, New York.

FoodMarble Logo
FoodMarble

FoodMarble has developed a personal digestive tracker. Based on validated clinical technology, this tiny breath test device and app can be used with the help of AI to help people work out what foods are most compatible with their unique digestive system.

Civica Rx Logo
Civica Rx

Civica Rx is a not-for-profit generic drug company that will help patients by addressing shortages and high prices of lifesaving generic medications.

Syntr Health Technologies Logo
Syntr Health Technologies

Syntr Health Technologies specializes in the micro fragmentation of adipose tissue for body contouring. The company was founded in 2016 and is based in Irvine, California.

H
HAPLN Science

HAPLN Science is a drug development company that focuses on anti-aging therapies that can reverse tissue and organ degeneration. The company's products include treatments for degenerative arthritis, skin aging treatment, hair loss, and connective tissue disease. HAPLN Science was founded in 2018 and is based in Seongnam, South Korea.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.